Member Info for AimSurfer007

With the recent director appointment surely the company is preparing for bigger opportunities and growth ahead?

Been thinking about that also. Do you top up now or wait for hopefully some profit taking post news. Hard to predict, this could gap up on news or present buying opportunity as some take profits. There seems to be strong demand past few days, I can sell large chucks but hard to buy in size. All it takes is one fund to decide this is a good level to buy and they will hoover everything up.

I guess we'll soon find out.

Once results are out raising money as and when needed I don't think won't be too difficult. Interestingly broker did forecast income from partnerships and collaborations in 2020, I wonder if they already have something lined up, just pending positive results.

I don't expect them needing significant funds for 2020, most of the cost seen last year was attributed to the trials.

They could simply sign partnership with someone in Asia to launch this product there and get significant initial payment plus royalty agreement. Hard to predict their strategy but I'm not worried about them having ability to raise a bit of cash.

CEO himself investing £75k in December so he's comfortable with the company's prospects.

Have a look at recent posts on ADVFN, comment there covered recent broker forecasts. With only 100 machines installed the company can generate almost $13m in recurring annual profit. Put that on PE of 10 and you have $130m value on this relative small number of installations. That's why I think we'll get bids for this company this year.

£30m for tech that had over $50m R&D spend plus successfully phase III trial is too cheap.

Two large buys printed from Friday? Not your pocket change investment.

Respectively disagree, would you be willing to bid £100m± for a company that has strong confidence of gaining phase III approval? You won't take that risk, I think phase III is higher risk compared to FDA approval. BTW I'm confident phase III will be a success given recent management purchases and reasons already shared here by other's. Once we have phase III approval out the way I expect the industry to treat FDA approval as formality and this share to attract serious interest from funds, investors and potential acquires.

Each unit is about $500k, so not cheap, that makes about $12m total spend on these research units. That's some serious industry validation.

Hospitals can actually save money with these machines. The average hospital stay for chronic obstructive pulmonary disease (‘COPD’) costs nearly US$11,000. Polarean’s technology could materially reduce hospitalisation rates by enabling earlier and more-accurate detection and treatment.

Is that a late reported £50k buy from Friday? Has to be a buy at 20p.

They are free sell as many as they can and have projects sales for 2020. But these machines can only be used for research and patients can't be charged until fda approval is in place. I expect next year to be busy with commercialisation planning and multiple potential collaborations to be announced.

This is directly from the company....

"We have said in the investor conference and elsewhere that we have active discussions with several different types of potential strategically interested parties. Any of those discussions could in theory be announced and even executed at any time, as they are able and free to draw their own conclusions about our risks in the trial readout and whether that is even important to them. For example we have said that several pharma groups we are talking to are interested in internal use regardless of the approval status."

Inverview out on Vox, sound's like a sensible approach to request pre nda meeting to dot the i's and cross the t's given current fda trend. Process could take much quicker if fda responses are timely. I support the companies approach, no need to rush the submission and then face delays if FDA have need clarity on anything.

I would hope with successful phase III trial out the way the market will value this company higher. If not I'm prepared to wait out in my bunker for fair value to be realised. Once rolled out they could easily be generating FCF equal to current mcap.

Could be traders moving on or some taking profits who got in at lower levels. Either way volume is low and the reward here is for those who wait for results, commercialisation news and FDA approval. It will easily do 100% from here. I'm happy to wait 12 months for those gains :) Sitting on your hands is sometimes the hardest decision.

Will be interesting to hear what the company says about the timelines now. Could the pre NDA work potentially reduce the FDA approval timeline? It took Blue Earth Diagnostics 8 months to get FDA approval but not sure if they took the pre NDA route or not.

I wouldn't mind few RockRose style acquisitions here. Below statement does indicate that's the type of deals new CEO is looking at?

"unique and game changing potential for the Company to partner with established regional players to participate in both late life and marginal field assets."

Indeed, after FDA approval the initial target market will be 1000 leading US teaching hospitals in pulmonary treatment. Only need a small fraction of that to have significant free cash flow. And we're completely excluding grow and collaboration agreement opportunities in EMEA and APAC.

Personally I would expect news on collaborations with entities in other regions and both drug and device manufacturers well before FDA approval. Company alluded in the past that conversations are happening.

Happy with my stake here and I think most shareholders know the future potential and will hold for big gains.

Current revenue is from selling polarisers to medical institutes for research purposes., they cost about $506k/unit. the company has sold about 25 of them to date.

After FDA approval majority of the revenue will come from fees per scan. Broker estimates US$41m in revenue and US$16m in Free Cash Flow with only 78 Clinical polarisers are installed.

The company has about 30 patents associated with this technology, these include Polarimetry patents, Automation patents, Pulmonary gas transfer patents.

My research shows currently no commercially viable competitors in the field of hyperpolarised gas MRI. Competitors will struggle to develop a competitive technology without infringing on Polarean IP, or commiting considerable investment into R&D. Furthermore upon FDA approval Polarean should receive five- years market excluvisity under the 1984 Hatch-Waxman Act.

GE invested US$40m into this technology but in 2012 decided to out licence the program due to an unclear pathway for regulatory approval of drug devices and internal reprioritisation of projects. Since then the US government passed the FDA Safety and Innovation Act and the Medical Gas Acts, which helped clarify the regulatory pathway for the clinical use of polarised gas imaging.

Interesting prints showing up now from yesterday, all buys?

Been reviewing recent broker notes that highlighted interesting opportunities.

"Polarean’s system may be of interest to drug-developers to develop a companion-diagnostic for expensive drugs to help inform clinicians as to which patients respond to treatment. A potential deal structure could include a partnership agreement to develop and commercialise image-based biomarkers driven by Polarean’s system for a certain disease indication (such as cystic fibrosis). This could include an upfront payment, funding of research activities, milestones payments and potential royalties on future net sales."

I think we could see some interesting announcements once the trial results are out.

Jonathan Allis who recently put in £200k into Polarean was the chief executive officer of Blue Earth Diagnostics. A molecular imaging technology company that was just sold for $450m. They completed trial III and had approval to sell into US and EMEA. Not saying we'll get to that value this year but shows me we have the right board who know how to commercialise imaging tech.